META-ANALYSIS OF PATIENTS (PTS) PREVIOUSLY TREATED WITH TAXANES FROM THREE RANDOMIZED TRIALS OF BEVACIZUMAB (BV) AND FIRST-LINE CHEMOTHERAPY AS TREATMENT FOR METASTATIC BREAST CANCER (MBC)

被引：0
|
作者：
Miles, D. W. [1 ]
Romieu, G. [2 ]
Dieras, V. [3 ]
Chen, D. [4 ]
Duenne, A. [5 ]
O'Shaughnessy, J. [6 ]
机构：
[1] Mt Vernon Canc Ctr, London, England
[2] CRLC Val Aurelle, Montpellier, France
[3] Inst Curie, Paris, France
[4] Genentech Inc, San Francisco, CA 94080 USA
[5] F Hoffmann La Roche Ltd, Basel, Switzerland
[6] Baylor Sammons Canc Ctr, Dallas, TX USA
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：97 / 97
页数：1
相关论文
共 50 条
  • [41] Risks and benefits of bevacizumab combined with chemotherapy for advanced or metastatic breast cancer: a meta-analysis of randomized controlled trials
    Miyashita, Minoru
    Hattori, Masaya
    Takano, Toshimi
    Toyama, Tatsuya
    Iwata, Hiroji
    [J]. BREAST CANCER, 2020, 27 (03) : 347 - 354
  • [42] Efficacy of Adding Bevacizumab in the First-Line Chemotherapy of Metastatic Colorectal Cancer: Evidence from Seven Randomized Clinical Trials
    Chen, Yan-xian
    Yang, Qiong
    Kuang, Jun-jie
    Chen, Shi-yu
    Wei, Ying
    Jiang, Zhi-min
    Xie, De-rong
    [J]. GASTROENTEROLOGY RESEARCH AND PRACTICE, 2014, 2014
  • [43] Rechallenge of patients previously treated with adjuvant anthracyclines using pegylated liposomal doxorubicin (PLD) with cyclophosphamide (C) as first-line chemotherapy for metastatic breast cancer (MBC)
    Trudeau, M.
    Clemons, M.
    Provencher, L.
    Panasci, L.
    Yelle, L.
    Rayson, D.
    Latreille, J.
    Vandenberg, T.
    Pouliot, J.
    [J]. BREAST, 2007, 16 : S54 - S54
  • [44] Bevacizumab for salvage treatment of metastatic breast cancer: a systemic review and meta-analysis of randomized controlled trials
    Lee, Jae-Bok
    Woo, Ok Hee
    Park, Kyong Hwa
    Woo, Sang Uk
    Yang, Dae Sik
    Kim, Ae-Ree
    Lee, Eun Sook
    Kim, Yeul Hong
    Kim, Jun Suk
    Seo, Jae Hong
    [J]. INVESTIGATIONAL NEW DRUGS, 2011, 29 (01) : 182 - 188
  • [45] Bevacizumab for salvage treatment of metastatic breast cancer: a systemic review and meta-analysis of randomized controlled trials
    Jae-Bok Lee
    Ok Hee Woo
    Kyong Hwa Park
    Sang Uk Woo
    Dae Sik Yang
    Ae-Ree Kim
    Eun Sook Lee
    Yeul Hong Kim
    Jun Suk Kim
    Jae Hong Seo
    [J]. Investigational New Drugs, 2011, 29 : 182 - 188
  • [46] Efficacy of chemotherapy plus bevacizumab as first-line therapy in patients with metastatic colorectal cancer: a meta-analysis and up-date
    Zhang, Guoliang
    Zhou, Xile
    Lin, Caizhao
    [J]. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2015, 8 (01): : 1434 - 1445
  • [47] Cardiac safety of the lapatinib/letrozole combination as first-line therapy in patients (pts) with metastatic breast cancer (MBC)
    Zembryki, D.
    Gomez, H.
    Koehler, M.
    Koehler, M.
    Johnston, S.
    Pippen, J.
    Florance, A.
    O'Rourke, L.
    Maltzman, J.
    Pivot, X.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [48] Anthracycline as second line chemotherapy (CT) for metastatic breast cancer (MBC) patients previously treated with taxotere (TXT)
    Delecroix, V
    Fumoleau, P
    Perrocheau, G
    Azli, N
    Fety, R
    Priou, F
    Maugard, C
    Riva, A
    Lemevel, B
    [J]. EUROPEAN JOURNAL OF CANCER, 1997, 33 : 666 - 666
  • [49] Safety of first-line systemic therapy in patients with metastatic colorectal cancer: a network meta-analysis of randomized controlled trials
    Zhan, Yanrong
    Cheng, Xianwen
    Mei, Pingping
    Tan, Shufa
    Feng, Wenzhe
    Jiang, Hua
    [J]. BMC CANCER, 2024, 24 (01)
  • [50] A Systematic Review and Meta-Analysis of Bevacizumab in First-Line Metastatic Breast Cancer: Lessons for Research and Regulatory Enterprises
    Hey, Spencer Phillips
    Gyawali, Bishal
    D'Andrea, Elvira
    Kanagaraj, Manoj
    Franklin, Jessica M.
    Kesselheim, Aaron S.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2020, 112 (04) : 335 - 342
12345